New Advances in Radioimmunotherapy for the Treatment of Cancers View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2020-09-25

AUTHORS

Clément Bailly , Caroline Bodet-Milin , Caroline Rousseau , François Guerard , Thomas Carlier , Ludovic Ferrer , Nicolas Chouin , Joelle Gaschet , Ferid Haddad , Michel Cherel , Jacques Barbet , Françoise Kraeber-Bodéré , Mickaël Bourgeois

ABSTRACT

Radioimmunotherapy (RIT) has been used for more than 30 years to diagnose and treat cancer. This approach consists of a targeted vectorization of a radionuclide by a monoclonal antibody to obtain specific irradiation of tumour cells. This approach has progressed significantly with the advances in immunological engineering, immunochemistry or radionuclides production. Radiolabelling of antibodies is well established and RIT protocols are a clinical and commercial reality for further indications. Today, the proof of efficacy for RIT in both haematologic malignancies and solid tumours was done, and RIT can be integrated into clinical practice for routine treatment of patients. RIT still has limitations but can be partially overcome, and high-dose treatment, new radionuclides, fractionated RIT or pretargeting approaches show promising clinical efficacy and increase the therapeutic index of radiolabelled antibodies. The alpha emitters offer the theoretical possibility to kill isolated tumour cells and eradicate the last microscopic clusters of tumour cells for residual disease therapy which is the final challenge in cancer therapy. The use of radiolabelled monoclonal antibodies could conduce to personalized dosimetry protocols by immuno-PET imaging and allows to select good responder patients and to optimize injected activity. More... »

PAGES

563-585

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-3-030-50287-4_29

DOI

http://dx.doi.org/10.1007/978-3-030-50287-4_29

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1131156221


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine, University Hospital\u00a0\u2013 CHU de Nantes, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.277151.7", 
          "name": [
            "INSERM UMR1232\u00a0\u2013 CNRS UMR6299\u00a0\u2013 Centre de Recherche en Canc\u00e9rologie de Nantes-Angers (Equipe 13), Institut de Recherche en Sant\u00e9 de l\u2019Universit\u00e9 de Nantes, Nantes, France", 
            "Department of Nuclear Medicine, University Hospital\u00a0\u2013 CHU de Nantes, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bailly", 
        "givenName": "Cl\u00e9ment", 
        "id": "sg:person.0665453076.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665453076.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine, University Hospital\u00a0\u2013 CHU de Nantes, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.277151.7", 
          "name": [
            "INSERM UMR1232\u00a0\u2013 CNRS UMR6299\u00a0\u2013 Centre de Recherche en Canc\u00e9rologie de Nantes-Angers (Equipe 13), Institut de Recherche en Sant\u00e9 de l\u2019Universit\u00e9 de Nantes, Nantes, France", 
            "Department of Nuclear Medicine, University Hospital\u00a0\u2013 CHU de Nantes, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bodet-Milin", 
        "givenName": "Caroline", 
        "id": "sg:person.01212260416.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01212260416.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine, ICO-Ren\u00e9 Gauducheau, Saint-Herblain, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "INSERM UMR1232\u00a0\u2013 CNRS UMR6299\u00a0\u2013 Centre de Recherche en Canc\u00e9rologie de Nantes-Angers (Equipe 13), Institut de Recherche en Sant\u00e9 de l\u2019Universit\u00e9 de Nantes, Nantes, France", 
            "Department of Nuclear Medicine, ICO-Ren\u00e9 Gauducheau, Saint-Herblain, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rousseau", 
        "givenName": "Caroline", 
        "id": "sg:person.01240530667.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240530667.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "INSERM UMR1232\u00a0\u2013 CNRS UMR6299\u00a0\u2013 Centre de Recherche en Canc\u00e9rologie de Nantes-Angers (Equipe 13), Institut de Recherche en Sant\u00e9 de l\u2019Universit\u00e9 de Nantes, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.4817.a", 
          "name": [
            "INSERM UMR1232\u00a0\u2013 CNRS UMR6299\u00a0\u2013 Centre de Recherche en Canc\u00e9rologie de Nantes-Angers (Equipe 13), Institut de Recherche en Sant\u00e9 de l\u2019Universit\u00e9 de Nantes, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Guerard", 
        "givenName": "Fran\u00e7ois", 
        "id": "sg:person.0673143706.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673143706.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine, University Hospital\u00a0\u2013 CHU de Nantes, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.277151.7", 
          "name": [
            "INSERM UMR1232\u00a0\u2013 CNRS UMR6299\u00a0\u2013 Centre de Recherche en Canc\u00e9rologie de Nantes-Angers (Equipe 13), Institut de Recherche en Sant\u00e9 de l\u2019Universit\u00e9 de Nantes, Nantes, France", 
            "Department of Nuclear Medicine, University Hospital\u00a0\u2013 CHU de Nantes, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carlier", 
        "givenName": "Thomas", 
        "id": "sg:person.01200407127.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01200407127.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine, ICO-Ren\u00e9 Gauducheau, Saint-Herblain, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "INSERM UMR1232\u00a0\u2013 CNRS UMR6299\u00a0\u2013 Centre de Recherche en Canc\u00e9rologie de Nantes-Angers (Equipe 13), Institut de Recherche en Sant\u00e9 de l\u2019Universit\u00e9 de Nantes, Nantes, France", 
            "Department of Nuclear Medicine, ICO-Ren\u00e9 Gauducheau, Saint-Herblain, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ferrer", 
        "givenName": "Ludovic", 
        "id": "sg:person.01112242163.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112242163.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AMaROC Research Group, ONIRIS (Nantes-Atlantic National College of Veterinary Medicine, Food Science and Engineering), Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.418682.1", 
          "name": [
            "INSERM UMR1232\u00a0\u2013 CNRS UMR6299\u00a0\u2013 Centre de Recherche en Canc\u00e9rologie de Nantes-Angers (Equipe 13), Institut de Recherche en Sant\u00e9 de l\u2019Universit\u00e9 de Nantes, Nantes, France", 
            "AMaROC Research Group, ONIRIS (Nantes-Atlantic National College of Veterinary Medicine, Food Science and Engineering), Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chouin", 
        "givenName": "Nicolas", 
        "id": "sg:person.01244363026.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01244363026.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "INSERM UMR1232\u00a0\u2013 CNRS UMR6299\u00a0\u2013 Centre de Recherche en Canc\u00e9rologie de Nantes-Angers (Equipe 13), Institut de Recherche en Sant\u00e9 de l\u2019Universit\u00e9 de Nantes, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.4817.a", 
          "name": [
            "INSERM UMR1232\u00a0\u2013 CNRS UMR6299\u00a0\u2013 Centre de Recherche en Canc\u00e9rologie de Nantes-Angers (Equipe 13), Institut de Recherche en Sant\u00e9 de l\u2019Universit\u00e9 de Nantes, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gaschet", 
        "givenName": "Joelle", 
        "id": "sg:person.0606471001.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0606471001.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GIP Arronax, Saint-Herblain, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Physics, Subatech, Ecole des M\u00eenes, University of Nantes, Nantes, France", 
            "GIP Arronax, Saint-Herblain, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Haddad", 
        "givenName": "Ferid", 
        "id": "sg:person.01225557150.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225557150.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine, ICO-Ren\u00e9 Gauducheau, Saint-Herblain, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "INSERM UMR1232\u00a0\u2013 CNRS UMR6299\u00a0\u2013 Centre de Recherche en Canc\u00e9rologie de Nantes-Angers (Equipe 13), Institut de Recherche en Sant\u00e9 de l\u2019Universit\u00e9 de Nantes, Nantes, France", 
            "Department of Nuclear Medicine, ICO-Ren\u00e9 Gauducheau, Saint-Herblain, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cherel", 
        "givenName": "Michel", 
        "id": "sg:person.01224071104.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224071104.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GIP Arronax, Saint-Herblain, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "INSERM UMR1232\u00a0\u2013 CNRS UMR6299\u00a0\u2013 Centre de Recherche en Canc\u00e9rologie de Nantes-Angers (Equipe 13), Institut de Recherche en Sant\u00e9 de l\u2019Universit\u00e9 de Nantes, Nantes, France", 
            "GIP Arronax, Saint-Herblain, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Barbet", 
        "givenName": "Jacques", 
        "id": "sg:person.01001654663.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001654663.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine, ICO-Ren\u00e9 Gauducheau, Saint-Herblain, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "INSERM UMR1232\u00a0\u2013 CNRS UMR6299\u00a0\u2013 Centre de Recherche en Canc\u00e9rologie de Nantes-Angers (Equipe 13), Institut de Recherche en Sant\u00e9 de l\u2019Universit\u00e9 de Nantes, Nantes, France", 
            "Department of Nuclear Medicine, University Hospital\u00a0\u2013 CHU de Nantes, Nantes, France", 
            "Department of Nuclear Medicine, ICO-Ren\u00e9 Gauducheau, Saint-Herblain, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kraeber-Bod\u00e9r\u00e9", 
        "givenName": "Fran\u00e7oise", 
        "id": "sg:person.0653324404.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653324404.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GIP Arronax, Saint-Herblain, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "INSERM UMR1232\u00a0\u2013 CNRS UMR6299\u00a0\u2013 Centre de Recherche en Canc\u00e9rologie de Nantes-Angers (Equipe 13), Institut de Recherche en Sant\u00e9 de l\u2019Universit\u00e9 de Nantes, Nantes, France", 
            "Department of Nuclear Medicine, University Hospital\u00a0\u2013 CHU de Nantes, Nantes, France", 
            "GIP Arronax, Saint-Herblain, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bourgeois", 
        "givenName": "Micka\u00ebl", 
        "id": "sg:person.0726751364.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726751364.15"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2020-09-25", 
    "datePublishedReg": "2020-09-25", 
    "description": "Radioimmunotherapy (RIT) has been used for more than 30\u00a0years to diagnose and treat cancer. This approach consists of a targeted vectorization of a radionuclide by a monoclonal antibody to obtain specific irradiation of tumour cells. This approach has progressed significantly with the advances in immunological engineering, immunochemistry or radionuclides production. Radiolabelling of antibodies is well established and RIT protocols are a clinical and commercial reality for further indications. Today, the proof of efficacy for RIT in both haematologic malignancies and solid tumours was done, and RIT can be integrated into clinical practice for routine treatment of patients. RIT still has limitations but can be partially overcome, and high-dose treatment, new radionuclides, fractionated RIT or pretargeting approaches show promising clinical efficacy and increase the therapeutic index of radiolabelled antibodies. The alpha emitters offer the theoretical possibility to kill isolated tumour cells and eradicate the last microscopic clusters of tumour cells for residual disease therapy which is the final challenge in cancer therapy. The use of radiolabelled monoclonal antibodies could conduce to personalized dosimetry protocols by immuno-PET imaging and allows to select good responder patients and to optimize injected activity.", 
    "editor": [
      {
        "familyName": "Rezaei", 
        "givenName": "Nima", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-3-030-50287-4_29", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-030-50286-7", 
        "978-3-030-50287-4"
      ], 
      "name": "Cancer Immunology", 
      "type": "Book"
    }, 
    "keywords": [
      "tumor cells", 
      "monoclonal antibodies", 
      "isolated tumor cells", 
      "promising clinical efficacy", 
      "good responder patients", 
      "high-dose treatment", 
      "radiolabelled monoclonal antibodies", 
      "immuno-PET imaging", 
      "proof of efficacy", 
      "responder patients", 
      "haematologic malignancies", 
      "clinical efficacy", 
      "treatment of cancer", 
      "routine treatment", 
      "RIT protocol", 
      "radiolabelled antibodies", 
      "therapeutic index", 
      "clinical practice", 
      "solid tumors", 
      "injected activity", 
      "radioimmunotherapy", 
      "antibodies", 
      "disease therapy", 
      "pretargeting approach", 
      "cancer therapy", 
      "patients", 
      "therapy", 
      "cancer", 
      "treatment", 
      "efficacy", 
      "new radionuclides", 
      "final challenge", 
      "specific irradiation", 
      "cells", 
      "microscopic clusters", 
      "further indication", 
      "malignancy", 
      "new advances", 
      "tumors", 
      "immunochemistry", 
      "alpha emitters", 
      "protocol", 
      "indications", 
      "imaging", 
      "years", 
      "advances", 
      "index", 
      "activity", 
      "use", 
      "practice", 
      "radionuclides", 
      "dosimetry protocols", 
      "theoretical possibility", 
      "irradiation", 
      "approach", 
      "production", 
      "limitations", 
      "challenges", 
      "possibility", 
      "clusters", 
      "proof", 
      "today", 
      "reality", 
      "commercial reality", 
      "emitters", 
      "engineering", 
      "vectorization"
    ], 
    "name": "New Advances in Radioimmunotherapy for the Treatment of Cancers", 
    "pagination": "563-585", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1131156221"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-3-030-50287-4_29"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-3-030-50287-4_29", 
      "https://app.dimensions.ai/details/publication/pub.1131156221"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-12-01T06:52", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/chapter/chapter_372.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-3-030-50287-4_29"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-3-030-50287-4_29'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-3-030-50287-4_29'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-3-030-50287-4_29'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-3-030-50287-4_29'


 

This table displays all metadata directly associated to this object as RDF triples.

230 TRIPLES      22 PREDICATES      92 URIs      84 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-3-030-50287-4_29 schema:about anzsrc-for:11
2 anzsrc-for:1107
3 anzsrc-for:1112
4 schema:author N9cc86de1072b404da661a307cbddf36f
5 schema:datePublished 2020-09-25
6 schema:datePublishedReg 2020-09-25
7 schema:description Radioimmunotherapy (RIT) has been used for more than 30 years to diagnose and treat cancer. This approach consists of a targeted vectorization of a radionuclide by a monoclonal antibody to obtain specific irradiation of tumour cells. This approach has progressed significantly with the advances in immunological engineering, immunochemistry or radionuclides production. Radiolabelling of antibodies is well established and RIT protocols are a clinical and commercial reality for further indications. Today, the proof of efficacy for RIT in both haematologic malignancies and solid tumours was done, and RIT can be integrated into clinical practice for routine treatment of patients. RIT still has limitations but can be partially overcome, and high-dose treatment, new radionuclides, fractionated RIT or pretargeting approaches show promising clinical efficacy and increase the therapeutic index of radiolabelled antibodies. The alpha emitters offer the theoretical possibility to kill isolated tumour cells and eradicate the last microscopic clusters of tumour cells for residual disease therapy which is the final challenge in cancer therapy. The use of radiolabelled monoclonal antibodies could conduce to personalized dosimetry protocols by immuno-PET imaging and allows to select good responder patients and to optimize injected activity.
8 schema:editor Nac403cdf029c47929e8581092fe6118a
9 schema:genre chapter
10 schema:isAccessibleForFree false
11 schema:isPartOf N9521fc4e0ff9423495fc71a972a1b90a
12 schema:keywords RIT protocol
13 activity
14 advances
15 alpha emitters
16 antibodies
17 approach
18 cancer
19 cancer therapy
20 cells
21 challenges
22 clinical efficacy
23 clinical practice
24 clusters
25 commercial reality
26 disease therapy
27 dosimetry protocols
28 efficacy
29 emitters
30 engineering
31 final challenge
32 further indication
33 good responder patients
34 haematologic malignancies
35 high-dose treatment
36 imaging
37 immuno-PET imaging
38 immunochemistry
39 index
40 indications
41 injected activity
42 irradiation
43 isolated tumor cells
44 limitations
45 malignancy
46 microscopic clusters
47 monoclonal antibodies
48 new advances
49 new radionuclides
50 patients
51 possibility
52 practice
53 pretargeting approach
54 production
55 promising clinical efficacy
56 proof
57 proof of efficacy
58 protocol
59 radioimmunotherapy
60 radiolabelled antibodies
61 radiolabelled monoclonal antibodies
62 radionuclides
63 reality
64 responder patients
65 routine treatment
66 solid tumors
67 specific irradiation
68 theoretical possibility
69 therapeutic index
70 therapy
71 today
72 treatment
73 treatment of cancer
74 tumor cells
75 tumors
76 use
77 vectorization
78 years
79 schema:name New Advances in Radioimmunotherapy for the Treatment of Cancers
80 schema:pagination 563-585
81 schema:productId N8f27b653b5ef42af9322eba0a5600e17
82 Na274275e49cf41c0a9e1e8b37bb18c8b
83 schema:publisher Ne530eca8bb3e469ea3600f0bb6c63fc8
84 schema:sameAs https://app.dimensions.ai/details/publication/pub.1131156221
85 https://doi.org/10.1007/978-3-030-50287-4_29
86 schema:sdDatePublished 2022-12-01T06:52
87 schema:sdLicense https://scigraph.springernature.com/explorer/license/
88 schema:sdPublisher N9b2036fbae07491aade57468bc6be53c
89 schema:url https://doi.org/10.1007/978-3-030-50287-4_29
90 sgo:license sg:explorer/license/
91 sgo:sdDataset chapters
92 rdf:type schema:Chapter
93 N12b55e73bb2e43cb8bb70d4fd891d7d8 rdf:first sg:person.01212260416.00
94 rdf:rest N4f2633818fe8492091edcc8dde83f2d1
95 N1ac5c2dd320a4089a90521b4f937bee1 rdf:first sg:person.0673143706.40
96 rdf:rest N91f35388c6ec4b2fba73d41f97a27822
97 N4f2633818fe8492091edcc8dde83f2d1 rdf:first sg:person.01240530667.47
98 rdf:rest N1ac5c2dd320a4089a90521b4f937bee1
99 N5ec021fa8ce24eb3a0f2498cc8798fa0 rdf:first sg:person.01001654663.28
100 rdf:rest Nae213e1b95294132a14f331860bafda4
101 N72928dbe14a043d0b0cc1c12494ab5e3 schema:familyName Rezaei
102 schema:givenName Nima
103 rdf:type schema:Person
104 N79ec913802904842a224043341f39a93 rdf:first sg:person.01224071104.01
105 rdf:rest N5ec021fa8ce24eb3a0f2498cc8798fa0
106 N7dcc8b863efa45168da5571e3c663c7f rdf:first sg:person.0606471001.16
107 rdf:rest Nfc3016af2f86485cb64fc51e6ec10705
108 N8f27b653b5ef42af9322eba0a5600e17 schema:name dimensions_id
109 schema:value pub.1131156221
110 rdf:type schema:PropertyValue
111 N91f35388c6ec4b2fba73d41f97a27822 rdf:first sg:person.01200407127.59
112 rdf:rest Nd2501dac7cb64be098551cd7bb951213
113 N9521fc4e0ff9423495fc71a972a1b90a schema:isbn 978-3-030-50286-7
114 978-3-030-50287-4
115 schema:name Cancer Immunology
116 rdf:type schema:Book
117 N9b2036fbae07491aade57468bc6be53c schema:name Springer Nature - SN SciGraph project
118 rdf:type schema:Organization
119 N9cc86de1072b404da661a307cbddf36f rdf:first sg:person.0665453076.40
120 rdf:rest N12b55e73bb2e43cb8bb70d4fd891d7d8
121 Na274275e49cf41c0a9e1e8b37bb18c8b schema:name doi
122 schema:value 10.1007/978-3-030-50287-4_29
123 rdf:type schema:PropertyValue
124 Nac403cdf029c47929e8581092fe6118a rdf:first N72928dbe14a043d0b0cc1c12494ab5e3
125 rdf:rest rdf:nil
126 Nad3d3d6ea7dd473488272a3148a3c496 rdf:first sg:person.01244363026.52
127 rdf:rest N7dcc8b863efa45168da5571e3c663c7f
128 Nae213e1b95294132a14f331860bafda4 rdf:first sg:person.0653324404.03
129 rdf:rest Nf4f51c55732942908b29ea9cb2aa9bab
130 Nd2501dac7cb64be098551cd7bb951213 rdf:first sg:person.01112242163.57
131 rdf:rest Nad3d3d6ea7dd473488272a3148a3c496
132 Ne530eca8bb3e469ea3600f0bb6c63fc8 schema:name Springer Nature
133 rdf:type schema:Organisation
134 Nf4f51c55732942908b29ea9cb2aa9bab rdf:first sg:person.0726751364.15
135 rdf:rest rdf:nil
136 Nfc3016af2f86485cb64fc51e6ec10705 rdf:first sg:person.01225557150.10
137 rdf:rest N79ec913802904842a224043341f39a93
138 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
139 schema:name Medical and Health Sciences
140 rdf:type schema:DefinedTerm
141 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
142 schema:name Immunology
143 rdf:type schema:DefinedTerm
144 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
145 schema:name Oncology and Carcinogenesis
146 rdf:type schema:DefinedTerm
147 sg:person.01001654663.28 schema:affiliation grid-institutes:None
148 schema:familyName Barbet
149 schema:givenName Jacques
150 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001654663.28
151 rdf:type schema:Person
152 sg:person.01112242163.57 schema:affiliation grid-institutes:None
153 schema:familyName Ferrer
154 schema:givenName Ludovic
155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112242163.57
156 rdf:type schema:Person
157 sg:person.01200407127.59 schema:affiliation grid-institutes:grid.277151.7
158 schema:familyName Carlier
159 schema:givenName Thomas
160 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01200407127.59
161 rdf:type schema:Person
162 sg:person.01212260416.00 schema:affiliation grid-institutes:grid.277151.7
163 schema:familyName Bodet-Milin
164 schema:givenName Caroline
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01212260416.00
166 rdf:type schema:Person
167 sg:person.01224071104.01 schema:affiliation grid-institutes:None
168 schema:familyName Cherel
169 schema:givenName Michel
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224071104.01
171 rdf:type schema:Person
172 sg:person.01225557150.10 schema:affiliation grid-institutes:None
173 schema:familyName Haddad
174 schema:givenName Ferid
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225557150.10
176 rdf:type schema:Person
177 sg:person.01240530667.47 schema:affiliation grid-institutes:None
178 schema:familyName Rousseau
179 schema:givenName Caroline
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240530667.47
181 rdf:type schema:Person
182 sg:person.01244363026.52 schema:affiliation grid-institutes:grid.418682.1
183 schema:familyName Chouin
184 schema:givenName Nicolas
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01244363026.52
186 rdf:type schema:Person
187 sg:person.0606471001.16 schema:affiliation grid-institutes:grid.4817.a
188 schema:familyName Gaschet
189 schema:givenName Joelle
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0606471001.16
191 rdf:type schema:Person
192 sg:person.0653324404.03 schema:affiliation grid-institutes:None
193 schema:familyName Kraeber-Bodéré
194 schema:givenName Françoise
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653324404.03
196 rdf:type schema:Person
197 sg:person.0665453076.40 schema:affiliation grid-institutes:grid.277151.7
198 schema:familyName Bailly
199 schema:givenName Clément
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665453076.40
201 rdf:type schema:Person
202 sg:person.0673143706.40 schema:affiliation grid-institutes:grid.4817.a
203 schema:familyName Guerard
204 schema:givenName François
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673143706.40
206 rdf:type schema:Person
207 sg:person.0726751364.15 schema:affiliation grid-institutes:None
208 schema:familyName Bourgeois
209 schema:givenName Mickaël
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726751364.15
211 rdf:type schema:Person
212 grid-institutes:None schema:alternateName Department of Nuclear Medicine, ICO-René Gauducheau, Saint-Herblain, France
213 GIP Arronax, Saint-Herblain, France
214 schema:name Department of Nuclear Medicine, ICO-René Gauducheau, Saint-Herblain, France
215 Department of Nuclear Medicine, University Hospital – CHU de Nantes, Nantes, France
216 Department of Physics, Subatech, Ecole des Mînes, University of Nantes, Nantes, France
217 GIP Arronax, Saint-Herblain, France
218 INSERM UMR1232 – CNRS UMR6299 – Centre de Recherche en Cancérologie de Nantes-Angers (Equipe 13), Institut de Recherche en Santé de l’Université de Nantes, Nantes, France
219 rdf:type schema:Organization
220 grid-institutes:grid.277151.7 schema:alternateName Department of Nuclear Medicine, University Hospital – CHU de Nantes, Nantes, France
221 schema:name Department of Nuclear Medicine, University Hospital – CHU de Nantes, Nantes, France
222 INSERM UMR1232 – CNRS UMR6299 – Centre de Recherche en Cancérologie de Nantes-Angers (Equipe 13), Institut de Recherche en Santé de l’Université de Nantes, Nantes, France
223 rdf:type schema:Organization
224 grid-institutes:grid.418682.1 schema:alternateName AMaROC Research Group, ONIRIS (Nantes-Atlantic National College of Veterinary Medicine, Food Science and Engineering), Nantes, France
225 schema:name AMaROC Research Group, ONIRIS (Nantes-Atlantic National College of Veterinary Medicine, Food Science and Engineering), Nantes, France
226 INSERM UMR1232 – CNRS UMR6299 – Centre de Recherche en Cancérologie de Nantes-Angers (Equipe 13), Institut de Recherche en Santé de l’Université de Nantes, Nantes, France
227 rdf:type schema:Organization
228 grid-institutes:grid.4817.a schema:alternateName INSERM UMR1232 – CNRS UMR6299 – Centre de Recherche en Cancérologie de Nantes-Angers (Equipe 13), Institut de Recherche en Santé de l’Université de Nantes, Nantes, France
229 schema:name INSERM UMR1232 – CNRS UMR6299 – Centre de Recherche en Cancérologie de Nantes-Angers (Equipe 13), Institut de Recherche en Santé de l’Université de Nantes, Nantes, France
230 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...